Adverum Biotechnologies Inc
NASDAQ:ADVM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.75
28.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Adverum Biotechnologies Inc
Adverum Biotechnologies Inc
Other Items
Adverum Biotechnologies Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adverum Biotechnologies Inc
NASDAQ:ADVM
|
Other Items
-$47.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$18.9B
|
CAGR 3-Years
-171%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$3.7B
|
CAGR 3-Years
31%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$26.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
-$2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-21%
|
|
Adverum Biotechnologies Inc
Glance View
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2014-07-31. The firm develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The firm's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
See Also
What is Adverum Biotechnologies Inc's Other Items?
Other Items
-47.1m
USD
Based on the financial report for Sep 30, 2024, Adverum Biotechnologies Inc's Other Items amounts to -47.1m USD.
What is Adverum Biotechnologies Inc's Other Items growth rate?
Other Items CAGR 5Y
-10%
You don't have any saved screeners yet
